Editor's Highlights—June 2025
International Journal of Dermatology · 2025
DOI: 10.1111/ijd.17836 ↗Kurz gefasst
Editorial in der Zeitschrift International Journal of Dermatology, 2025. Verfasst von Lajos Kemény. Beteiligte Einrichtung: Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary. Hauptthemen laut MEDLINE: Dermatologic Agents, Skin Diseases. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Advances in inflammatory skin disease management are rapidly redefining dermatologic practice. This issue presents a compelling framework unifying type 2 inflammation across conditions like atopic dermatitis, prurigo nodularis, and chronic urticaria, emphasizing shared cytokine pathways and therapeutic opportunities. Also featured here is new real‐world evidence supporting dupilumab efficacy following tralokinumab failure. In psoriasis, a novel “step‐down” treatment strategy advocates for earlier biologic use in younger patients, followed by de‐escalation. A paired commentary tempers this proposal with methodological and practical concerns. Finally, data on bimekizumab's safety and effectiveness in patients with chronic kidney disease address a critical clinical gap. These contributions highlight a shift toward precision medicine, integrating immunologic insight with patient age, comorbidity profiles, and therapeutic sequencing to inform truly individualized care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
ORCID-Profile: Lajos Kemény
Zitieren
APA
Kemény, L. (2025). Editor's Highlights—June 2025. International Journal of Dermatology. https://doi.org/10.1111/ijd.17836
Vancouver
Kemény L. Editor's Highlights—June 2025. International Journal of Dermatology. 2025. doi:10.1111/ijd.17836
BibTeX
@article{Kemny2025,
author = {Kemény, Lajos},
title = {Editor's Highlights—June 2025},
journal = {International Journal of Dermatology},
year = {2025},
doi = {10.1111/ijd.17836}
}
EUVIMED